Loading...
TARO logo

Taro Pharmaceutical Industries Ltd.NYSE:TARO Rapporto sulle azioni

Cap. di mercato US$1.6b
Prezzo delle azioni
n/a
1Y10.2%
7D0.4%
1D0%
Valore del portafoglio
​
Vista

Taro Pharmaceutical Industries Ltd.

Report azionario NYSE:TARO

Capitalizzazione di mercato: US$1.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Taro Pharmaceutical Industries (TARO) Panoramica del titolo

A science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. Maggiori dettagli

TARO analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura0/6
Prestazioni passate3/6
Salute finanziaria6/6
Dividendi0/6

Premi

Negoziato a 93.3% al di sotto della nostra stima del suo valore equo

Gli utili sono cresciuti del 111.7% nell'ultimo anno

Analisi del rischio

Gli utili sono diminuiti del 15.7% all'anno negli ultimi 5 anni

Grandi elementi una tantum che incidono sui risultati finanziari


TARO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW475,526 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
475,526 investors already sharing narratives
View all narratives

Concorrenti di Taro Pharmaceutical Industries Ltd.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Taro Pharmaceutical Industries
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$42.97
Massimo di 52 settimaneUS$45.76
Minimo di 52 settimaneUS$32.67
Beta0.56
Variazione di 1 mese0.66%
Variazione a 3 mesi1.97%
Variazione di 1 anno10.21%
Variazione a 3 anni-40.56%
Variazione a 5 anni-50.36%
Variazione dall'IPO759.40%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Dec 12

Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity

Summary Taro Pharmaceutical Industries is a hidden treasure in the pharmaceutical industry, with a Strong Buy Quant Rating and positive financials. The company has been overshadowed by Teva Pharmaceutical Industries but has potential for growth in its niche. Taro's recent earnings report showed increased sales and profitability, making it an attractive investment opportunity. Read the full article on Seeking Alpha
Seeking Alpha • Aug 16

Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)

Summary Taro Pharmaceutical's minority shareholders have resisted Sun Pharmaceuticals' offer of $38 per share, stating that Taro is worth more. Taro's operating economics are unattractive in my view, with declining pre-tax earnings and no revenue growth. Uncertainty remains on the Sun Pharma bid, placing uncertainty on price visibility. Revise to hold. Read the full article on Seeking Alpha
Seeking Alpha • Jun 02

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Summary Taro received a $38/share offer from Sun Pharma last month. The deal represents a decent premium to the firm's market value at the time and a 12% premium to my estimate of fair value. Further insights reveal the deal could be valuable to Taro shareholders given all the contributing factors. With the new catalyst in place, I am revising the position to buy, not discounting the potential for a competing bid either. Read the full article on Seeking Alpha
Seeking Alpha • Feb 24

Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold

Summary Taro Pharmaceutical's quarterly numbers came in with very thin growth at the operating and bottom-lines given the impact from settlement charges. Price erosion in its U.S. generics business continues to be a headwind. Question is, does the stock represent value at these compressed multiples. We sought to understand the same, and found the data supports a neutral view. Investment Summary Israeli-based pharmaceutical companies are at the forefront of innovation and drug development globally. Not all opportunities are created equal, however. For those investors restricted to investing in U.S. exchanges, Taro Pharmaceutical Industries Ltd (TARO) has been an underwhelming performer versus key benchmarks over the last 6-years to date [Figure 1]. The company posted its Q3' results last month with flat top-line growth and a substantial decrease in earnings after it booked another round of non-operating losses in its cash flow statement and P&L. As a reminder, these charges fall on the back of charges filed by the Department of Justice ("DOJ") in 2020' for conspiring to "fix prices, allocate customers, and rig bids for generic drugs". The charges came after TARO admitted to participating in "two charged conspiracies between 2013 and 2015", combined with a "second conspiracy with a generic drug company based in Pennsylvania and other individuals, from at least as early as May 2013 and continuing until at least December 2015". The outcome was a part of a wider DOJ investigation where a total of 6 companies were charged with antitrust conspiracies related to drug pricing on sales into the U.S. As a result, TARO, along with its co-conspirator, agreed to pay a collective $426mm in penalties. Subsequently, its bottom-line has been materially impacted by the decision, leading to negligent post-tax earnings growth since FY20'. The question is, at 0.7x book value, does the company represent a potential value play, or are there too many headwinds in the picture? Here, we sought to extrapolate the latest data to gauge this. Alas, given the culmination of reasons presented in this report, the data supports that TARO stock is currently a hold. It has a large reversal ahead of itself in order to achieve a positive re-rating, meaning that investors are unlikely to be attracted to the stock until we see evidence of the same. Fig. (1) TARO price performance FY17–date Data: Updata TARO Q4 results analytics Turning to the latest set of numbers, its prudent to perform a rigorous examination of TARO's growth percentages to see how it fared with and without the settlement charges involved. Looking in greater detail, with respect to the P&L, we'd note the following data points as key takeaways: Quarterly net sales came in flat YoY to $139mm as the cost of sales increased 19.4% to $75mm. To this point, TARO noted it continues to "experience price pressures particularly in the U.S. generic business" alas the price erosion in its generics footprint continues to be a remarkable headwind to top-line growth. This reflects the points raised earlier that were raised in the DOJ investigations. We see further evidence of this as gross profit clamped ~15% YoY to $64mm, leading to an 8.7 percentage point compression in quarterly gross margin to 46%. In a high-inflation environment, this could be a meaningful risk to profitability and earnings growth down the line, should this trend continue. TARO pared back R&D expenditure as a result of the above to ~9.3% of turnover. It also lost leverage at the SG&A line with a $25mm YoY increase to ~$50mm in general expenditures. It's important to note that these expenditures include adjustments made for the company's Alchemee acquisition, a consumer products company, back in February FY22 on a $99mm valuation. As to the success of the acquisition, we've been unable to see an organic view of the company's performance given the settlement charges discussed here. Moving down the P&L, and the impact from its generics' price erosion listed above are abundantly clear. It recognized a $35.7mm headwind from downsides in its U.S. generics franchise, clipping just $1.3mm in quarterly income on a razor thin 0.94% operating margin. Looking at the 9-months to December FY22, the overall impact was a $33mm headwind, where the company booked $42mm in operating income. Again, talking in terms of margin growth, this is a substantial headwind that must be worked through. We don't believe a further sub-1% operating margin is sustainable for the company without a) eating through substantial cash, or b) at least having to pare back operations substantially. It pulled this down to earnings of $7.3mm, a 72.2% YoY decline that came to $0.19 in EPS. Again, scrutinizing the 9-month numbers, TARO clipped $18.5mm in net income, a 40% YoY pullback to $0.49 per share. The trailing earnings yield on this is just 1.6%, well below the S&P 500's trailing earnings yield of ~4.6%. This was further realized at the cash flow level, as it clipped a substantial wind-back in CFFO of $175mm or 87.5% YoY to $24.9mm with another $54mm burnt in on-balance sheet cash. Again, the cash flow yield on this is a paltry 2.17%. The firm is still well capitalized with a combined $1.2Bn in cash and short-term and long-term equivalents, however. Still, for investors searching for quality, growth, or even value, it's hard to see an alignment with any of these factors, and the obvious pullback in bottom-line fundamentals is further support of a neutral view. It is important to note these operating bottom-line results include the impact from its settlement and contingency charges listed earlier. Subsequently, it's important to make adjustments for the settlement payments. We refer investors to Figure 2 for the breakdown: Fig. (2) TARO reported numbers vs. settlement-adjusted [9-months to December 2022] Note: All figures are shown in $mm'. (Data: Author, adapted from TARO Q3 financial results)
Seeking Alpha • Jan 24

Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M

Taro Pharmaceutical press release (NYSE:TARO): Q3 GAAP EPS of $0.19 misses by $0.68. Revenue of $139.2M misses by $23.92M.
Seeking Alpha • Oct 28

Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M

Taro Pharmaceutical press release (NYSE:TARO): FQ2 Non-GAAP EPS of $0.66 misses by $0.18. Revenue of $130.5M (-11.3% Y/Y) misses by $30.52M. Gross profit of $47.0M (36.0% of net sales) compared to $62.0M (47.0% of net sales). As of September 30, 2022, cash and cash equivalents, short-term bank deposits and marketable securities (both short- and long-term) decreased $58.9M to $1.2B from March 31, 2022.
Seeking Alpha • Aug 15

Taro Pharmaceutical hits 52-week low; down 28% YTD

Taro Pharmaceutical (NYSE:TARO) on Monday hit a 52-week low of $32.50. The Israeli drugmaker, known for marking generic and over-the-counter products, is down ~28% year to date. Taro (TARO) beat on the top and bottom lines in its Q2 2022 results at the end of July.
Seeking Alpha • Jul 27

Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M

Taro Pharmaceutical press release (NYSE:TARO): Q2 Non-GAAP EPS of $1.09 beats by $0.24. Revenue of $156.7M (+6.5% Y/Y) beats by $6.8M.
Seeking Alpha • Jul 14

Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

Based on the current long-term trend, shares look like they will test long-term support. We expect support to hold there based on the company's strong earnings power and clean balance sheet. Adjusted cash flow numbers also remain strong. Investors may need to buy the fear here when the situation presents itself. If we pull up a long-term technical chart of Taro Pharmaceutical Industries Ltd. (TARO), we can see that shares remain above the stock's multi-year trend line which dates back all the way to 1998. This essentially means that shares remain in a long-term bull market despite the fact that shares have been making lower lows consistently for some time now. However, given the fact that we see no significant bullish divergences at present in either the RSI momentum indicator or indeed the MACD, the likelihood is that shares will test long-term support depicted below which may mean the $30 level approx may come into view here before a final long-term bottom is printed. Although long-term charts are not useful for trading purposes, what they do provide is insights into the underlying trend of the stock which simply cannot be ascertained from more short-term timeframes. Although short-term charts can be very much emotionally driven, multi-decade charts address far more information where rationality and psychology (Human states which generally do not change) are much more to the fore. Suffice it to say, our job is to decipher whether indeed Taro Pharmaceutical would be a strong buy at the $30 level. We can gain insights into this answer by monitoring the company's trends regarding its earnings and linking this to the company's valuation in general. Remember, Taro has no debt on its balance sheet which means interest expenses can not erode the company's net profit to any significant degree. Furthermore, the fact the shares are presently trading under book value permits us to focus on the company's earnings expectations and particularly what is expected in this present fiscal year (ends March 2023) Long-Term Chart Of Taro Pharmaceutical (Stockcharts.com) Being chartists, we believe Taro's share price action on the technical chart is a full reflection of the stock's known fundamentals such as but not limited to the recent DOJ investigations and subsequent cash payments, the recent Alchemee purchase, and the current competitive pressures which exist in this industry. In spite of these headwinds, the company reported a net profit of $58.3 million for its most recent fiscal year (which ended March 2022). However, it is the forward earnings multiple of 9.75 which has really caught our attention for the following reason. Cheap Earnings Earnings growth is the main driver of stock prices, period. Given that the above earnings multiple corresponds to projected earnings of $3.86 per share, Taro´s forward earnings yield comes in at (Projected Earnings/Stock Price - 3.86/37.62) 10.26%. This 10.26% projected yield equates to the investor´s rate of return if indeed management decided to pay out all of its earnings to shareholders. Taking into account however our $30 entry point, our projected annual yield would now increase to 12.87%. Now, given how Taro's U.S. market, in particular, may potentially not live up to expectations due to significant competitive pressures, that 12%+ forward earnings yield has to be taken with a grain of salt. We get this but even if we are wrong, there is still plenty of buffer between that projection and the prevailing inflation rate. Remember, with high single-digit inflation rates continuing to be the norm at present, investors will undoubtedly begin to price this new narrative into their positions. Suffice it to say, it is all about real returns going forward so double-digit nominal returns from certain equities are bound to come under extra scrutiny going forward from investors. Cash Flow When we look at the most recent year-end cash flow statement, we see that net cash of almost $159 million was actually used in the fiscal year. However, when we take out monies associated with loss contingencies and the settlement, we see that the adjusted operating cash flow number comes to a positive $165 million number. Although a forward cash-flow multiple can not be predicted at present due to the uncertainty regarding ongoing civil antitrust issues, the adjusted trailing operating cash-flow multiple for example comes in at 8.61.
Articolo di analisi • Aug 03

We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

Taro Pharmaceutical Industries Ltd.'s ( NYSE:TARO ) solid earnings announcement recently didn't do much to the stock...
Articolo di analisi • Jan 26

A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

Taro Pharmaceutical Industries Ltd. ( NYSE:TARO ) shareholders should be happy to see the share price up 24% in the...

Rendimenti per gli azionisti

TAROUS PharmaceuticalsUS Mercato
7D0.4%-0.9%0.5%
1Y10.2%50.6%16.5%

Ritorno vs Industria: TARO ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 50.6 % nell'ultimo anno.

Rendimento vs Mercato: TARO ha avuto una performance inferiore al mercato US che ha registrato un rendimento 16.5 % nell'ultimo anno.

Volatilità dei prezzi

Is TARO's price volatile compared to industry and market?
TARO volatility
TARO Average Weekly Movement0.6%
Pharmaceuticals Industry Average Movement9.2%
Market Average Movement7.2%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Prezzo delle azioni stabile: TARO non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 1% ) di TARO è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
19591,554Uday Baldotawww.taro.com

Taro Pharmaceutical Industries Ltd. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Taro Pharmaceutical Industries con la sua capitalizzazione di mercato?
TARO statistiche fondamentali
Capitalizzazione di mercatoUS$1.62b
Utili (TTM)US$53.87m
Ricavi(TTM)US$629.18m
30.0x
Rapporto P/E
2.6x
Rapporto P/S

TARO è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
TARO Conto economico (TTM)
RicaviUS$629.18m
Costo del fatturatoUS$324.20m
Profitto lordoUS$304.98m
Altre speseUS$251.11m
UtiliUS$53.87m

Ultimi utili riportati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)1.43
Margine lordo48.47%
Margine di profitto netto8.56%
Rapporto debito/patrimonio netto0%

Come si è comportato TARO nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/06/24 06:58
Prezzo dell'azione a fine giornata2024/06/24 00:00
Utili2024/03/31
Utili annuali2024/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Taro Pharmaceutical Industries Ltd. è coperta da 3 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Randall StanickyGoldman Sachs
Raghuram SelvarajuH.C. Wainwright & Co.
Kenneth CacciatoreTD Cowen